Ding Yuling, Wang Yanmei, Jeon Byong-Tae, Moon Sang-Ho, Lee Seung-Hong
Department of Animal Bio and Applied Chemistry, Konkuk University, Chungju, 27478, Republic of Korea.
Jilin Sino-Rok Institue of Animal Science, Changchun, 130-600, China.
EXCLI J. 2017 Mar 22;16:328-339. doi: 10.17179/excli2016-638. eCollection 2017.
The purpose of the current study was to investigate the potential anti-obesity activity of an enzymatic hydrolysate of velvet antler in inhibiting adipogenesis in 3T3-L1 cells and in high-fat diet (HFD)-fed obese mice. The enzymatic hydrolysate was prepared using the commercial food grade protease, Protamex. The velvet antler Protamex hydrolysate (VAPH) indicated profound inhibitory effects on adipogenesis dose-dependently by decreasing the accumulation of triglycerides and down-regulating expression levels of adipogenesis-related proteins C/EBPα, SREBP-1, and PPARγ. In a mouse model of HFD-induced obesity, oral administration of VAPH (100 and 300 mg/kg for 13 weeks) significantly reduced the body weight gain that had resulted from the HFD. VAPH treatment also lowered the serum glucose and triglyceride levels, while increasing the HDL-C level. Furthermore, the treatment greatly reduced hepatic lipid droplet accumulation as well as the size of adipocytes. Current findings demonstrate that VAPH has profound anti-obesity effects and could be an effective candidate for preventing obesity and obesity-related chronic diseases.
本研究的目的是探讨鹿茸酶解物在抑制3T3-L1细胞脂肪生成以及高脂饮食(HFD)喂养的肥胖小鼠脂肪生成方面的潜在抗肥胖活性。酶解物是使用商业食品级蛋白酶Protamex制备的。鹿茸Protamex酶解物(VAPH)通过减少甘油三酯的积累和下调脂肪生成相关蛋白C/EBPα、SREBP-1和PPARγ的表达水平,对脂肪生成表现出显著的剂量依赖性抑制作用。在HFD诱导的肥胖小鼠模型中,口服VAPH(100和300 mg/kg,持续13周)显著降低了HFD导致的体重增加。VAPH治疗还降低了血清葡萄糖和甘油三酯水平,同时提高了HDL-C水平。此外,该治疗大大减少了肝脏脂质滴的积累以及脂肪细胞的大小。目前的研究结果表明,VAPH具有显著的抗肥胖作用,可能是预防肥胖及肥胖相关慢性疾病的有效候选物。